ArriVent BioPharma logo
ArriVent BioPharma
AVBP | NASDAQ
Chart Builder DCF Calculator
$11.56
-$1.45 (-11.15%)
At close: Nov 16, 2026, 4:00 PM ET
$11.56
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

ArriVent BioPharma Company Profile

Company profile explained

Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Key Executives

Name Position
Zhengbin Yao Co-Founder, Chairman, President & Chief Executive Officer
Robin LaChapelle Co-Founder & Chief Operating Officer
Winston Kung Chief Financial Officer & Treasurer
Yang Wang Chief Technology Officer
Brent S. Rice Chief Commercial Officer
James Paul Kastenmayer General Counsel & Secretary
Stuart Lutzker Co-Founder, President of Research & Development and Director

Latest SEC Filings

Date Type Title
Oct 26, 2026 8-K Current Report
Oct 19, 2026 8-K Current Report
Oct 13, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 13, 2026 8-K Current Report
Oct 08, 2026 SC 13D/A [Amend] Filing
Oct 06, 2026 8-K Current Report
Aug 12, 2026 10-Q Quarterly Report
Aug 12, 2026 8-K Current Report
Jul 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 22, 2026 4 Filing
View All SEC Filings ➞
ArriVent BioPharma
ArriVent BioPharma logo
Country United States
IPO Date Jan 26, 2024
Industry Biotechnology
Sector Healthcare
Employees 77
CEO Zhengbin Yao

Contact Details

18 Campus Boulevard Suite 100 Newtown Square, Pennsylvania 19073 United States

Stock Details

Ticker Symbol AVBP
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001868279
CUSIP Number 04272N102
ISIN Number US04272N1028
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.